Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab
Study sponsor: Omeros Corporation
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-10-10Actual
Enrollment · participants12Actual
Source updated2025-10-01Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.